Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma |
| |
Authors: | Yuan-Qing Zhang Jin-Sheng Guo Division of Digestive Diseases |
| |
Affiliation: | Yuan-Qing Zhang;Jin-Sheng Guo;Division of Digestive Diseases,Department of Internal Medicine,Zhong Shan Hospital,Shanghai Medical College,Fu Dan University; |
| |
Abstract: | Chronic hepatitis B virus (HBV) infection is a critical risk factor for the carcinogenesis and progression of hepatocellular carcinoma (HCC). It promotes HCC development by inducing liver fibrogenesis, genetic and epigenetic alterations, and the expression of active viral-coded proteins. Effective antiviral treatments inhibit the replication of HBV, reduce serum viral load and accelerate hepatitis B e antigen serum conversion. Timely initiation of antiviral treatment is not only essential for preventing the incidence of HCC in chronic hepatitis B patients, but also important for reducing HBV reactivation, improving liver function, reducing or delaying HCC recurrence, and prolonging overall survival of HBV-related HCC patients after curative and palliative therapies. The selection of antiviral drugs, monitoring of indicators such as HBV DNA and hepatitis B surface antigen, and timely rescue treatment when necessary, are essential in antiviral therapies for HBV-related HCC. |
| |
Keywords: | Chronic hepatitis B Hepatocellular carcinoma Antiviral therapy |
本文献已被 CNKI 等数据库收录! |
|